SynthesisOral health & preventive dentistry2026
Contribution of Resveratrol on Periodontal Disease Control and Treatment: A Systematic Review.
Synthesis in Oral health & preventive dentistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeResveratrol, a natural polyphenol with anti-inflammatory and antioxidant properties, has been proposed as an adjunctive agent in periodontal therapy. This systematic review aimed to evaluate the effectiveness of resveratrol in controlling periodontal inflammation and alveolar bone loss in preclinical and clinical studies. METHODS AND MATERIALS: A systematic review was conducted following PRISMA 2020 guidelines. Electronic databases (PubMed/MEDLINE, Cochrane Library, Lilacs, Wiley, ScienceDirect) were searched up to October 2025, complemented by manual searches of periodontal journals. Eligible studies included in vivo animal experiments and randomised clinical trials assessing the impact of resveratrol on periodontal outcomes. Three reviewers independently performed study screening, data extraction, and risk-of-bias assessment using SYRCLE and Cochrane tools.
resultsTwenty-two studies met the inclusion criteria, including 16 preclinical and 6 clinical studies. In animal models, resveratrol consistently reduced alveolar bone loss (7.09% to 60.60%) and improved inflammatory and oxidative stress markers. Clinical trials reported variable but generally positive effects, including reductions in probing pocket depth, bleeding index, and plaque index, and improvements in clinical attachment level. Several studies also showed decreased systemic or local inflammatory cytokines. Clinical evidence remains limited by small sample sizes, methodological heterogeneity, and short follow-up periods. No clinical study evaluated radiographic bone loss.
conclusionPreclinical studies suggest that resveratrol has anti-inflammatory, antioxidant and bone-protective effects, but clinical evidence is limited and heterogeneous. Resveratrol may be considered as an adjunct to nonsurgical periodontal therapy, particularly in aggressive periodontitis but further well-designed trials are needed to determine optimal dosage, duration, and delivery route to support its potential as a complementary therapy for periodontitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.